Nicardipine is a dihydropyridine calcium channel blocker developed during the 1970s as part of efforts to improve upon earlier agents like Nifedipine, with the goal of achieving greater vascular selectivity and better tolerability. It was patented in 1976, and subsequent preclinical and clinical studies in the late 1970s demonstrated its effectiveness in dilating coronary and peripheral blood vessels. Clinical trials in the early 1980s confirmed its usefulness in treating hypertension and angina, leading to its approval for medical use around 1981–1982 in different countries, although an exact universal approval month is not consistently documented. Over the following decades, nicardipine became widely adopted in both oral and intravenous forms, with the intravenous formulation gaining particular importance in hospital settings for managing acute hypertension, hypertensive emergencies, and blood pressure control in neurological conditions such as stroke. Today, it remains a well-established and widely used medication in cardiovascular and critical care practice worldwide, supported by decades of clinical experience.
BRAND NAMES
Nicardipine is marketed under several brand names worldwide, including:
Cardene (most well-known brand, especially for IV use)
CardeneSR (sustained-release formulation)
Nicardia
Nicardia Retard
Nicarb
Angiocard (in some regions)
MECHANISM OF ACTION
Nicardipine works by blocking L-type calcium channels in vascular smooth muscle, reducing the entry of calcium ions into cells. This leads to relaxation of arterial smooth muscle, causing vasodilation, decreased peripheral resistance, and a reduction in blood pressure, while having minimal direct effect on cardiac conduction.
PHARMACOKINETICS
Absorption
Nicardipine is well absorbed after oral administration, but it undergoes extensive first-pass metabolism in the liver, which reduces its systemic bioavailability to about 10–35%. Because of this, oral formulations are usually designed as sustained-release tablets to maintain more stable blood levels. When given intravenously, absorption is immediate and complete since it directly enters the circulation.
Distribution
Nicardipine is widely distributed throughout the body after absorption because it is highly lipophilic and extensively binds to plasma proteins (about 95% or more, mainly albumin and alpha-1 acid glycoprotein). This strong protein binding keeps most of the drug in the bloodstream while the free (active) fraction exerts pharmacological effects on vascular smooth muscle. It has a relatively large volume of distribution, indicating extensive tissue uptake, including vascular tissues where it produces its antihypertensive action.
Metabolism
Nicardipine is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system, especially CYP3A4. It undergoes hepatic oxidation to form inactive metabolites, meaning very little unchanged drug is excreted in urine. Because of this high first-pass hepatic metabolism, its oral bioavailability is relatively low, and liver function or drugs that inhibit or induce CYP3A4 can significantly affect its plasma levels and therapeutic effect.
Elimination
Nicardipine is eliminated mainly through the kidneys, but almost entirely as inactivemetabolites, not as unchanged drug. A smaller portion of metabolites is also excreted in feces via bile. Its terminal elimination half-life is relatively short (about 2–4 hours), which is why continuous infusion or sustained-release oral formulations are often used to maintain stable blood pressure control.
PHARMACODYNAMICS
Nicardipine produces its pharmacodynamic effects by selectively blocking L-type calcium channels in vascular smooth muscle. This reduces calcium entry into cells, leading to relaxation of arterial smooth muscle and marked vasodilation, especially in peripheral and coronary arteries. The main effect is a reduction in systemic vascular resistance and blood pressure, with relatively little direct depression of cardiac contractility or conduction. Because of rapid vasodilation, it can sometimes trigger a mild reflex increase in heart rate. Overall, its pharmacodynamic profile is characterized by potent arterial vasodilation, antihypertensive action, and improved blood flow to vital organs without significant cardiac suppression.
ADMINISTRATION
Nicardipine is administered in both oral and intravenous (IV) forms depending on the clinical situation. The oral form is given as immediate-release or sustained-release tablets, usually taken multiple times daily or once/twice daily in extended-release form for long-term management of hypertension or angina. The IV formulation is used in hospital settings as a continuous infusion for rapid control of severe hypertension or hypertensive emergencies, where the dose is carefully titrated based on blood pressure response.
DOSAGE AND STRENGTH
Nicardipine is available in both oral and intravenous formulations, and its dosage depends on the clinical condition being treated. For oral use, it is commonly given as immediate-release tablets in 20 mg doses taken three times daily, or as sustained-release tablets in 30 mg or 60 mg strengths taken once or twice daily, with gradual dose adjustments based on blood pressure response. In hospital settings, the intravenous form is used for rapid control of severe hypertension, starting as a continuous infusion at about 5 mg/hour and titrated upward by small increments depending on the patient’s response, usually not exceeding 15 mg/hour under close monitoring.
DRUG INTERACTIONS
Nicardipine is mainly metabolized by CYP3A4, so most of its drug interactions involve agents that inhibit or induce this enzyme or drugs that also affect blood pressure or heart rate.
Important drug interactions:
CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, ritonavir) → increase nicardipine levels, leading to excessive hypotension and side effects
CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) → decrease effectiveness by lowering drug levels
Other antihypertensives (beta-blockers, ACE inhibitors, diuretics) → additive blood pressure lowering effect, may cause hypotension
Digoxin → nicardipine may increase digoxin levels in some cases, requiring monitoring
Cyclosporine/tacrolimus → may have increased levels when used with nicardipine, increasing toxicity risk
FOOD INTERACTIONS
Nicardipine has minimal food interactions, and it can be taken with or without food. The main concern is grapefruit or grapefruit juice, which inhibits CYP3A4 and can increase drug levels, potentially leading to excessive hypotension and side effects. Other normal foods do not significantly affect its action.
CONTRAINDICATIONS
Nicardipine is contraindicated in patients with known hypersensitivity to the drug or other dihydropyridine calcium channel blockers. It should be avoided in cases of severe aortic stenosis because the vasodilation can worsen cardiac output. It is also contraindicated in unstable angina or acute myocardial infarction when not managed in a controlled setting, as excessive vasodilation may lead to reflex tachycardia and worsen ischemia
SIDE EFFECTS
Headache
Flushing
Dizziness
Hypotension
Peripheral edema
OVER DOSAGE
Severe hypotension
Reflex tachycardia
Dizziness
Syncope
Weakness
Flushing
TOXICITY
Nicardipine toxicity results from excessive vasodilation and leads mainly to severe hypotension, reflex tachycardia, dizziness, flushing, and in serious cases circulatory collapse or shock. It may also cause syncope, weakness, and rarely myocardial ischemia.
